In addition, plasma and cerebrospinal fluid (CSF) phosphorylated tau (p-tau), particularly its isoform p-tau181 and p-tau217, are recognized as potential biomarker for early onset AD in preclinical settings and the level of p-tau has been associated with the intensity of tauopathy [24–29]. The gene discussed is MAPT; the disease is Alzheimer disease.